Allergic asthma is among the most common immune-mediated diseases across the world,
and type 2 immune responses are thought to be central to pathogenesis. The importance of …

The development of monoclonal antibody therapies targeting specific components of the
pathways relevant to asthma pathophysiology has revolutionized treatment of severe …

Background: Insufficient data are available on the long-term “real-life” safety profile of
omalizumab in children. This study evaluated the long-term safety of omalizumab in a …

Introduction In recent years, monoclonal antibodies targeting Type-2 inflammatory pathways
have been developed for severe asthma treatment. However, even when patients are …

Background The mainstay of treatment for eosinophilic granulomatosis with polyangiitis
(EGPA) is systemic corticosteroid therapy; some patients also receive intravenous …

Objective: To evaluate the clinical efficacy and safety of combining omalizumab with
budesonide formoterol to treat children with moderate and severe allergic asthma, and …

重度哮喘是哮喘患者致死和致残的主要因素, 可造成巨大的社会和经济压力. 近年来,
随着对哮喘病理机制的深入了解, 生物靶向治疗逐渐成为重度哮喘治疗的新选择 …

Severe asthma stands as a formidable contributor to both mortality and morbidity of patients
suffering asthma, casting substantial social and economic shadows on communities. As our …

Background: The mainstay of treatment for eosinophilic granulomatosis with polyangiitis
(EGPA) is systemic corticosteroid therapy; some patients also receive intravenous …